Keap1-Nrf2

Nrf2-IN-1 (Compound 4f) is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2), acts as a promising agent in acute myeloid leukemia (AML) therapy.

AEM1 is an inhibitor of deregulated NRF2 transcriptional activity in cancer.